title: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
abstract: The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. Investigators have since also used NST as an in vivo test for chemosensitivity by assessing pathologic complete response. Today, by using pathologic response and other biomarkers as intermediate end points, results from trials of new regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials. In 2003, a panel of representatives from various breast cancer clinical research groups was first convened in Biedenkopf to formulate recommendations on the use of NST. The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report.
authors.affiliation: Department of Gynecology and Obstetrics and Breast Unit, Goethe University, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
authors.forename: Manfred
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.forename: Elefhterios P
authors.initials: EP
authors.lastname: Mamounas
authors.forename: David
authors.initials: D
authors.lastname: Cameron
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Carey
authors.forename: Massimo
authors.initials: M
authors.lastname: Cristofanilli
authors.forename: Carsten
authors.initials: C
authors.lastname: Denkert
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Eiermann
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.forename: Jay R
authors.initials: JR
authors.lastname: Harris
authors.forename: Thomas
authors.initials: T
authors.lastname: Karn
authors.forename: Cornelia
authors.initials: C
authors.lastname: Liedtke
authors.forename: Davide
authors.initials: D
authors.lastname: Mauri
authors.forename: Roman
authors.initials: R
authors.lastname: Rouzier
authors.forename: Eugen
authors.initials: E
authors.lastname: Ruckhaeberle
authors.forename: Vladimir
authors.initials: V
authors.lastname: Semiglazov
authors.forename: W Fraser
authors.initials: WF
authors.lastname: Symmans
authors.forename: Andrew
authors.initials: A
authors.lastname: Tutt
authors.forename: Lajos
authors.initials: L
authors.lastname: Pusztai
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001706:Biopsy; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000592:standards* / Q000639:trends*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005544:Forecasting; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000592:standards* / Q000639:trends*; D017410:Practice Guidelines as Topic